Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Saved in:
| Title: | Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study. |
|---|---|
| Authors: | Montalban X; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain., Piasecka-Stryczynska K; Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland., Kuhle J; Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital Basel, Basel, Switzerland; University of Basel, Basel, Switzerland., Benkert P; Clinical Trial Unit, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland., Arnold DL; Montreal Neurological Institute, McGill University, Montreal, QC, Canada; NeuroRx, Montreal, QC, Canada., Weber MS; Institute of Neuropathology, Department of Neurology, University Medical Center, University of Göttingen, Göttingen, Germany; Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP, Göttingen, Germany., Seitzinger A; Merck Healthcare KGaA, Darmstadt, Germany., Guehring H; Merck Healthcare KGaA, Darmstadt, Germany., Shaw J; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA., Tomic D; Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA., Hyvert Y; Merck Healthcare KGaA, Darmstadt, Germany., Harlow DE; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA., Dyroff M; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA., Wolinsky JS; McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA. |
| Source: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2024 Apr; Vol. 30 (4-5), pp. 558-570. Date of Electronic Publication: 2024 Mar 04. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article |
| Journal Info: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1477-0970 |
|---|---|
| DOI: | 10.1177/13524585241234783 |
